Sirolimus‐induced interstitial lung disease following pediatric stem cell transplantation |
| |
| Authors: | Andrea S. Garrod Rakesh K. Goyal Daniel J. Weiner |
| |
| Affiliation: | 1. Division of Pediatric Respiratory Medicine, Department of Pediatrics, University of Virginia, Charlottesville, VA, USA;2. Blood and Marrow Transplantation and Cellular Therapies, Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA;3. Divisions of Pulmonary Medicine, Allergy and Immunology, Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA |
| |
| Abstract: | ![]()
Sirolimus‐induced ILD is a known but rare complication in adults who have undergone SOT. However, little is known about this adverse effect in children. Diagnosis of sirolimus‐induced ILD can be challenging, especially in patients who have difficulty participating in lung function testing. We present a case of presumed sirolimus‐induced ILD in a pediatric stem cell transplant patient who developed polycythemia and hypoxemia. To our knowledge, no other cases of sirolimus‐induced pulmonary toxicity in children after HCT have been reported. |
| |
| Keywords: | pediatrics hematopoietic stem cell transplantation sirolimus interstitial lung disease lung function tests |
|
|
